Etanercept for Treatment of Psoriasis and Psoriatic Arthritis

Therapy of Moderate-to-Severe Psoriasis, Second Edition, Revised and Expanded

Volumn , Issue , 2003, Pages 261-286

  Gottlieb, Alice B ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 12444289660     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b14220-16     Document Type: Chapter

References (60)

1. Gottlieb AB, Matheson RT, Lowe NJ, Zitnik RJ. Efficacy of Enbrel in patients with psoriasis. J Invest Dermatol 2002; 119:234.
2. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356(9227):385–390.
3. Mease P, Kivitz A, Burch F, Siegel E, Cohen S, Burge D. Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (ENBREL): results of a phase 3 multicenter clinical trial [abstract]. Arthritis Rheum 2001; 44(suppl):S90–A 226.
4. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999; 341(24):1817–1828.
5. Baugh JA, Bucala R. Mechanisms for modulating TNFa in immune inflammatory disease. Curr Opin Drug Disc Dev 2001; 4:635–650.
6. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999; 38: 241–251.
7. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46(1):1–23.
8. Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem 1987; 262(15):6951–6954.
9. Pennica D, Kohr WJ, Fendly BM, Shire SJ, Raab HE, Borchardt PE, Lewis M, Goeddel DV. Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptor: evidence for tumor necrosis factor-alpha induced receptor aggregation. Biochemistry 1992; 31(4): 1134–1141.
10. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175(2):323–329.
11. Foerder CA, Rogge MC. Immunogenicity of Enbrel (Etanercept): clinical trial observations. EULAR 2002; abstract THU0032.
12. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151(3): 1548–1561.
13. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991; 174(6):1483–1489.
14. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151(11):6602–6607.
15. Enbrel (etanercept) [package insert]. 05/2002. 2002. Seattle, Washington, Immunex Corporation and Wyeth-Ayerst Pharmaceuticals.
16. Moreland LW, Cohen S, Fleischmann RM, Baumgartner SW, Schiff MH, Burge DJ. Safety and efficacy of up to 5 Years of Etanercept (Enbrel) therapy in rheumatoid arthritis. EULAR 2002; abstract FRI0078.
17. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130(6):478–486.
18. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate [see comments]. N Engl J Med 1999; 340(4):253–259.
19. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343(22):1586–1593.
20. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group [see comments]. N Engl J Med 2000; 342(11):763–769.
21. Gorman JD, Sack KE, Davis JC, Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346(18): 1349–1356.
22. Marzo-Ortega H, McGonagle D, O’Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001; 44(9):2112–2117.
23. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25:1544–1552.
24. Partsch F, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24:518–523.
25. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96(1):146–151.
26. Mussi A, Bonifati C, Carducci M, D’Agosto G, Pimpinelli F, D’Urso D, D’Auria L, Fazio M, Ameglio F. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997; 11(3):115–118.
27. Bonifati C, Carduci M, Cordiali Fei P, Trento E, Sacerdoti G, Fazio M, Ameglio F. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients—relationships with disease severity. Clin Exp Dermatol 1994; 19(5):383–387.
28. Wakefield PE, James WD, Samlaska CP, Meltzer MS. Tumor necrosis factor. J Am Acad Dermatol 1991; 24(5 Pt 1):675–685.
29. Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol 1991; 127(6):871–884.
30. Aggarwal BB, Natarajan K. Tumor necrosis factors: developments during the last decade. Eur Cytokine Network 1996; 7(2):93–124.
31. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162(6):2163–2168.
32. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986; 319(6053):516–518.
33. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986; 322(6079):547–549.
34. Shinmei M, Masuda K, Kikuchi T, Shimomura Y. The role of cytokines in chondrocyte mediated cartilage degradation. J Rheumatol Suppl 1989; 18:32–34.
35. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol 1988; 73(3):449–455.
36. Brennan FM, Chantry D, Jackson AM, Maini RN, Feldmann M. Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun 1989; 2 Suppl:177–186.
37. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14:397–440.
38. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992; 89(16):7375–7379.
39. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89(20):9784–9788.
40. Saxne T, Palladino MA, Jr., Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31(8):1041–1045.
41. Husby G, Williams RC, Jr. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1988; 1(4):363–371.
42. Brennan FM, Maini RN, Feldmann M. TNF alpha—a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992; 31(5):293–298.
43. Neidel J, Schulze M, Lindschau J. Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor alpha in the knee-joints of patients with rheumatoid arthritis. Inflamm Res 1995; 44(5):217–221.
44. Deleuran BW. Cytokines in rheumatoid arthritis. Localization in arthritic joint tissue and regulation in vitro. Scand J Rheumatol Suppl 1996; 104:1–34.
45. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000; 51:207–229.
46. Catrina AI, Lampa J, Ernestam S, Af Klint E, Bratt J, Klareskog L, Ulfgren AK. Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) downregulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) 2002; 41(5):484–489.
47. Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002; 61(4): 298–304.
48. Gladman DD. Psoriatic arthritis. In: Maddison PJ, Isenberg DA, Glass DN, eds. Oxford Textbook of Rheumatology. Oxford: Oxford University Press, 1998: 1071.
49. Gladman DD. Psoriatic arthritis. Rheum Dis Clin North Am 1998; 24(4): 829–844.
50. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3(1): 55–78.
51. Dougados M, van Der LS, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Dijkmans B, Olivieri I, Pasero G, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34(10):1218–1227.
52. Salvarani C, Lo Scocco G, Macchioni P, Cremonesi T, Rossi F, Mantovani W, Battistel B, Bisighini G, Portioli I. Prevalence of psoriatic arthritis in Italian psoriatic patients. J Rheumatol 1995; 22(8):1499–1503.
53. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36(6):729–740.
54. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman-Mak E, Blackburn WD, Vasey FB, Mahowald ML, Cush JJ, Schumacher HR Jr, Silverman SL, Alepa FP, Luggen ME, Cohen MR, Makkena R, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39(12):2013–2020.
55. Gottlieb AB, Lowe NJ, Matheson RT, Lebsack ME. Efficacy of etanercept in patients with psoriasis. Presented at the American Academy of Dermatology, New Orleans, LA, Feb 22–27, 2002.
56. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40(7):1202–1209.
57. Klareskog L, Moreland LM, Cohen SB, Sanda M, Burge DJ. Global safety and efficacy of up to five years of etanercept (EnbrelR) therapy [abstract]. Arthritis Rheum 2001; 44(suppl):S77–Abstract 150.
58. Gray DT, Suman VJ, Su WP, Clay RP, Harmsen WS, Roenigk RK. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol 1997; 133(6):735–740.
59. Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985–1996. J Am Acad Dermatol 2001; 45(4): 528–536.
60. Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica 1978; 157(4):238–244.